[Cyclosporin A as a diabetogenic cofactor]

Area of Science:

• Nephrology
• Endocrinology
• Immunosuppression

Background:

• Kidney transplantation requires immunosuppressive therapy to prevent organ rejection.
• Cyclosporine A is a widely used calcineurin inhibitor in post-transplant care.
• Maintaining therapeutic drug levels is crucial for efficacy and safety.

Observation:

• Two kidney transplant recipients developed new-onset insulin-dependent diabetes mellitus.
• This complication occurred when serum Cyclosporine A levels exceeded therapeutic ranges.
• Diabetes symptoms resolved completely after Cyclosporine A levels were reduced and stabilized.

Findings:

• Cyclosporine A, at elevated concentrations, is implicated as a direct initiator of insulin-dependent diabetes mellitus.
• The diabetogenic effect of Cyclosporine A appears to be reversible.
• This suggests a direct toxic or modulatory effect on pancreatic beta-cells.

Implications:

• Clinicians should monitor blood glucose levels closely in kidney transplant patients on Cyclosporine A.
• Therapeutic drug monitoring of Cyclosporine A is critical to prevent adverse endocrine effects.
• Further research is warranted to elucidate the precise mechanism of Cyclosporine A-induced diabetes.